PMID- 36568756
OWN - NLM
STAT- MEDLINE
DCOM- 20221227
LR  - 20230126
IS  - 2296-2565 (Electronic)
IS  - 2296-2565 (Linking)
VI  - 10
DP  - 2022
TI  - Reduced antibody response to COVID-19 vaccine composed of inactivated SARS-CoV-2 
      in diabetic individuals.
PG  - 1025901
LID - 10.3389/fpubh.2022.1025901 [doi]
LID - 1025901
AB  - BACKGROUND: Patients with type 2 diabetes mellitus (T2DM) are at increased risk 
      for COVID-19 related morbidity and mortality. Antibody response to COVID-19 
      vaccine in T2DM patients is not very clear. The present work aims to evaluate the 
      antibody response to the inactivated SARS-CoV-2 vaccine in this population. 
      METHODS: Two groups of subjects with no history of SARS-CoV-2 infection were 
      included: 63 T2DM patients and 56 non-T2DM controls. Each participant received 
      two doses of inactivated COVID-19 vaccine. IgG antibodies against the 
      nucleocapsid (N) and spike (S) proteins of SARS-CoV-2 (anti-N/S IgG) and receptor 
      binding domain (RBD) proteins (anti-RBD IgG) were quantitatively evaluated by the 
      electrochemiluminescence immunoassays, respectively. RESULTS: It was observed 
      that the positive rates and titers of anti-N/S IgG and anti-RBD IgG in T2DM 
      patients were significantly lower than those in controls, respectively (anti-N/S: 
      85.7 vs. 98.2%, P = 0.034; 25.48 vs. 33.58 AU/ml P = 0.011; anti-RBD: 85.7 vs. 
      96.4%, P = 0.044; 15.45 vs. 22.25 AU/ml, P = 0.019). Compared to non-T2DM 
      subjects, T2DM patients with uncontrolled glycemia showed lower positive antibody 
      rates and titers (anti-N/S IgG: 75% and 13.30 AU/ml; anti-RBD IgG: 75% and 11.91 
      AU/ml, respectively, all P < 0.05), while T2DM patients with controlled glycemia 
      had similar positive antibody rates and titers (anti-N/S IgG: 94.3% and 33.65 
      AU/ml; and anti-RBD IgG: 94.3% and 19.82 AU/ml, respectively, all P > 0.05). 
      CONCLUSION: In the analysis performed, the data indicate that T2DM patients with 
      uncontrolled glycemia showed a lower level of IgG antibodies compared to 
      non-diabetic controls and individuals with controlled glycemia when immunized 
      with the inactivated COVID-19 vaccine.
CI  - Copyright (c) 2022 Cheng, Shen, Tao, Zhang, Xu, Bi, Han and Zhou.
FAU - Cheng, Yandong
AU  - Cheng Y
AD  - Department of Endocrinology, Nanjing Drum Tower Hospital, Nanjing University 
      Medical School, Nanjing, Jiangsu, China.
FAU - Shen, Ping
AU  - Shen P
AD  - Department of Laboratory Medicine, Nanjing Drum Tower Hospital, Nanjing 
      University Medical School, Nanjing, Jiangsu, China.
FAU - Tao, Yue
AU  - Tao Y
AD  - Department of Laboratory Medicine, Nanjing Drum Tower Hospital, Nanjing 
      University Medical School, Nanjing, Jiangsu, China.
FAU - Zhang, Wenjun
AU  - Zhang W
AD  - Department of Laboratory Medicine, Nanjing Drum Tower Hospital, Nanjing 
      University Medical School, Nanjing, Jiangsu, China.
FAU - Xu, Biyun
AU  - Xu B
AD  - Department of Biomedicine Statistics, Nanjing Drum Tower Hospital, Nanjing 
      University Medical School, Nanjing, Jiangsu, China.
FAU - Bi, Yan
AU  - Bi Y
AD  - Department of Endocrinology, Nanjing Drum Tower Hospital, Nanjing University 
      Medical School, Nanjing, Jiangsu, China.
FAU - Han, Zhen
AU  - Han Z
AD  - Department of Prevention and Health Care, Nanjing Drum Tower Hospital, Nanjing 
      University Medical School, Nanjing, Jiangsu, China.
FAU - Zhou, Yi-Hua
AU  - Zhou YH
AD  - Department of Laboratory Medicine, Nanjing Drum Tower Hospital, Nanjing 
      University Medical School, Nanjing, Jiangsu, China.
AD  - Department of Infectious Diseases and Jiangsu Key Laboratory for Molecular 
      Medicine, Nanjing Drum Tower Hospital, Nanjing University Medical School, 
      Nanjing, Jiangsu, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221208
PL  - Switzerland
TA  - Front Public Health
JT  - Frontiers in public health
JID - 101616579
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Immunoglobulin G)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2
MH  - COVID-19 Vaccines
MH  - SARS-CoV-2
MH  - Antibody Formation
MH  - *COVID-19/prevention & control
MH  - Immunoglobulin G
PMC - PMC9773130
OTO - NOTNLM
OT  - COVID-19
OT  - T2DM patients
OT  - impaired antibody response
OT  - inactivated SARS-CoV-2
OT  - vaccination
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/12/27 06:00
MHDA- 2022/12/28 06:00
PMCR- 2022/12/08
CRDT- 2022/12/26 03:59
PHST- 2022/08/23 00:00 [received]
PHST- 2022/11/23 00:00 [accepted]
PHST- 2022/12/26 03:59 [entrez]
PHST- 2022/12/27 06:00 [pubmed]
PHST- 2022/12/28 06:00 [medline]
PHST- 2022/12/08 00:00 [pmc-release]
AID - 10.3389/fpubh.2022.1025901 [doi]
PST - epublish
SO  - Front Public Health. 2022 Dec 8;10:1025901. doi: 10.3389/fpubh.2022.1025901. 
      eCollection 2022.